Overview

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Status:
Recruiting

Trial end date:
2028-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

ADC Therapeutics S.A.

Treatments:

Gemcitabine
Loncastuximab tesirine
Oxaliplatin
Rituximab